August 14, 2019
July 29, 2019
ATRYS obtains funding from CDTI for research in liquid biopsy in prostate cancer
Madrid, July 29, 2019.
ATRYS HEALTH (“ATRYS”) has obtained the support of the CDTI for the financing of its research project SURVEPROST, througth the call for UNILATERAL international collaboration projects. In this collaboration, ATRYS joins its R&D efforts with DINÁMICA (GRUPO SURA), a leading diagnostic company in Colombia, to develop a molecular firm in liquid biopsy for active surveillance in prostate cancer, SURVEPROST.
July 8, 2019
ATRYS issues bonds for 25 million euros
June 10, 2019
ATRYS intends to lead the Smart / Big Data in health with the integration of Real Life Data
ATRYS HEALTH, S.A. ("ATRYS"), a company listed on the MAB and included in the IBEX® MAB-15 index, dedicated to diagnostic services and medical treatments of excellence, has closed the acquisition of 100% of REAL LIFE DATA SLU, leader in Smart/Big Data in the health sector in Spain.
The transaction is a determining step for ATRYS and consolidates it as a reference in the provision of Smart/Big Data services and data management in the health sector. This acquisition will allow adding a new dimension to the medical services currently provided by ATRYS, with which it generates more than one million diagnostic reports per year. The operation will enhance the work of ATRYS in the field of predictive medicine, reinforcing its R&D area and developing knowledge about the evolution and dimension of pathologies, trends in diagnoses and treatments.
March 4, 2019
Financial Times includes Atrys Health among the 1000 fastest growing companies in Europe
Atrys Health, S.A., a company dedicated to the provision of diagnostic services and precision medical treatments, has been included in the 'FT 1000: Europe's Fastest-Growing Companies' ranking, prepared by the prestigious British newspaper Financial Times. A study that highlights the companies that act as a driving force of the European economy.